


Drugs For Peptic Ulcer

Dr. Mohammed Al-Sbou
Professor of clinical Pharmacology
Faculty of Medicine, Mutah University

Peptic Ulcer Disease (PUD)

- ▶ **Peptic ulcers** commonly involve stomach (**gastric**) **ulcer** or **duodenum (duodenal) ulcer**
- ▶ The most common symptom is **burning stomach pain**
- ▶ Complications is **bleeding**
- ▶ **Relapse is common when treatment is stopped**



Major Causative Factors

- ▶ Long-term use of aspirin & NSAIDs (elderly)
- ▶ Infection with gram negative *Helicobacter pylori*
- ▶ Increased hydrochloric acid (HCL) secretion
- ▶ Steroids, smoking, alcohol, stress

Treatment Approach

- ▶ Eradicate *H. pylori* infection
- ▶ **Reduce gastric acid secretion**
 - H₂-receptor antagonists
 - Proton pump inhibitors (PPIs)
- ▶ Agents that protect gastric mucosa from damage such as **misoprostol and sucralfate**
- ▶ Patients unable to tolerate above therapies, neutralized gastric acid with **antacids**



- ▶ **The goals of treatment for peptic ulcer:**
 - Relieve pain
 - Heal ulcer
 - Prevent recurrence and complications

Classes of Drugs to Treat PUD

- ▶ **Antimicrobial agents:** Amoxicillin, clarithromycin, metronidazole, tetracycline
- ▶ **H₂ receptor blockers:** cimetidine, famotidine, ranitidine
- ▶ **Proton pump inhibitors (PPIs):** esomeprazole, lansoprazole, omeprazole, pantoprazole
- ▶ **Prostaglandins:** misoprostol
- ▶ **Antacids:** Aluminum hydroxide, magnesium hydroxide, calcium carbonate
- ▶ **Mucosal protective agents:** Bismuth subsalicylate, sucralfate

Antimicrobial Agents

- ▶ Useful for patients with **PU infected with H. pylori**
- ▶ **Diagnosis of H.pylori:** Endoscopic biopsy of gastric mucosa, serological tests, urea breath tests
- ▶ **Eradication of H.pylori** results in **rapid healing of active peptic ulcer, low recurrence rate and reduce risk of bleeding**
- ▶ Successful eradication **80-90%**



- ▶ **Combination therapy:**
- ▶ **Triple therapy:** PPI, clarithromycin, plus either amoxicillin or metronidazole
- ▶ **Quadrable therapy:** PPI, metronidazole, tetracycline, bismuth subsalicylate
- ▶ Duration: for **2-week course**
- ▶ **GERD (Gastroesophageal reflux disease) (heartburn sensation) is not associated with H.pylori infection** and does not response to treatment with antibiotics

H2-Recptor Antagonists


- ▶ **Cimetidine, famotidine (famodar), ranitidine (zantac)**
- ▶ **Block actions of histamine** at all **H2 receptors**
- ▶ **Completely inhibit gastric acid secretion** induced by histamine or gastrin
- ▶ Uses of these agents has **decreased with the use of PPIs**
- ▶ **Therapeutic uses:**
 - ▶ Healing of Peptic ulcers
 - ▶ Prevention & treatment of GERD (50% no benefit, use PPIs)

- ▶ All H₂ antagonists can be given **orally or IV**
- ▶ **Cimetidine: short half-life, inhibits CYP P450** (slow metabolism of warfarin, diazepam, phenytoin, carbamazepine)
- ▶ **Ranitidine: longer half-life, more potent than cimetidine**
- ▶ **Famotidine:** similar to ranitidine, 20-50 more potent than cimetidine
- ▶ They need **45 mins to relieve symptoms**
- ▶ Dose should be reduced in **hepatic and renal failure**

- ▶ **Side effects:**
- ▶ Headache, dizziness, diarrhea, muscular pain
- ▶ **CNS:** confusion, hallucinations (elderly, after IV administration)
- ▶ **Cimetidine: Endocrine (antiandrogen)** effects (gynecomastia, galactorrhea, reduced sperm count, impotence) **(limited use)**

Proton pump inhibitors (PPIs)

- ▶ **Omeprazole, esomeprazole (Nexium), lansoprazole, pantoprazole**
- ▶ Bind to **H/K ATPase (proton pump)** of parietal cell, suppressing secretion of hydrogen ions into gastric lumen
- ▶ **PPIs superior than H₂ antagonists in suppression of acid production and peptic ulcer healing**



Therapeutic Uses

- ▶ Eradication of *H. pylori*
- ▶ GERD
- ▶ Prevention & treatment of NSAIDs-induced ulcer
- ▶ Reduce risk of bleeding from NSAIDs-induced ulcer
- ▶ Erosive esophagitis
- ▶ Active duodenal ulcer
- ▶ Hypersecretion conditions (Zollinger-Ellison syndrome: gastrin – producing tumor causes hypersecretion of HCL)

- ▶ Should be taken **30 mins before meal**
- ▶ Acid suppression takes **1-2 hrs**
- ▶ **Given orally** (sustained release formulation)
- ▶ **Intravenous injections**
- ▶ **Omeprazole** inhibits metabolism of warfarin, phenytoin, diazepam, cyclosporine

- ▶ **Adverse effects:**
- ▶ Flatulence, diarrhea, Clostridium difficile colitis
- ▶ Dry mouth, sleep disturbances, taste disturbances
- ▶ Prolonged therapy: low B12

Prostaglandins

- ▶ **Prostaglandins E2**, produced by gastric mucosa, **inhibits secretion of HCL, stimulates secretion of mucus and bicarbonate** (cytoprotective effect)
- ▶ **Misoprostol (Cytotec)** is analog of prostaglandin E1
- ▶ **Uses:** prevention of NSAID-induced ulcers (elderly, patients with ulcer complications)
- ▶ **Less effective than H2 antagonists and PPIs for acute treatment of peptic ulcer**

- ▶ **Adverse effects:** Diarrhea, nausea, abdominal pain
- ▶ **Misoprostol** produces uterine contractions, **contraindicated during pregnancy**

Antacids

- ▶ **Aluminum hydroxide (Maalox) , magnesium hydroxide, calcium carbonate**
- ▶ **React with gastric acid to form water and salt, diminish gastric acidity**
- ▶ **Uses:** They are used as **last-line therapy for GERD, duodenal ulcer**
- ▶ **Adverse effects:**
- ▶ Aluminum hydroxide: constipation
- ▶ Magnesium hydroxide: diarrhea

Mucosal Protective Agents

- ▶ **Bismuth subsalicylate, sucralfate**
- ▶ **Cytoprotective compounds, enhances mucosal protection,** prevent mucosal injury, reduce inflammation, healing ulcers
- ▶ **Sucralfate:**
- ▶ Complex of **aluminum hydroxide and sulfate sucrose**
- ▶ Form gel with epithelia cells, creates physical barrier that impairs diffusion of HCL
- ▶ Stimulate prostaglandin release

- ▶ **Heals duodenal ulcers**, long-term therapy to prevent recurrence
- ▶ **Should not be administered with H2 antagonists or antacids** (requires acidic PH for activation)